An Overview of Amyotrophic Lateral Sclerosis

This episode of JAMA Clinical Reviews provides a comprehensive overview of amyotrophic lateral sclerosis (ALS), a rare, progressive neurodegenerative disease characterized by the degeneration of motor neurons, leading to muscle weakness and eventual loss of function. Dr. John Rabbits, a neurologist and ALS translational research leader at UC San Diego, explains the clinical presentation—often beginning with focal weakness, slurred speech, or limb involvement—and emphasizes the importance of recognizing the coexistence of upper and lower motor neuron signs, such as spasticity and fasciculations, during physical exams. The diagnosis is clinical and one of exclusion, requiring imaging to rule out mimics like spinal cord compression and EMG to confirm denervation. Dr. Rabbits discusses the two main forms of ALS—sporadic (85%) and familial (15%), with the latter having implications for genetic testing and family counseling. He highlights recent advances in treatment, including Riluzol, Edaravone, and the gene-targeted therapy Tofersen, which shows promise in SOD1-mutated cases. The episode also underscores the critical role of multidisciplinary care teams in managing symptoms like dysphagia, dysarthria, and respiratory decline, with early interventions such as voice banking and gastrostomy tube placement improving quality of life. Finally, Dr. Rabbits expresses optimism about ongoing research into ALS pathophysiology and the potential for transformative therapies. Key takeaways include: ALS is a clinical diagnosis requiring exclusion of mimics; early multidisciplinary care significantly improves patient outcomes; genetic testing is increasingly important for familial cases and treatment eligibility; Tofersen represents a breakthrough for SOD1-related ALS; and proactive interventions—like voice banking and early G-tube placement—enhance quality of life. The episode concludes on a hopeful note, emphasizing the active global research landscape and the potential for future disease-modifying therapies.